| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Howard Donninger | |
| Geoffrey J Clark | |||
| M Lee Schmidt | |||
| Thibaut Barnoud | |||
| Jessica Mezzanotte | |||
| P2860 | cites work | PML regulates p53 acetylation and premature senescence induced by oncogenic Ras | Q22254666 |
| MAP-1, a novel proapoptotic protein containing a BH3-like motif that associates with Bax through its Bcl-2 homology domains | Q24290468 | ||
| The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1 | Q24292345 | ||
| A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP) | Q24293710 | ||
| Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, Raf-1, and Akt | Q24296477 | ||
| The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt1 | Q24297392 | ||
| Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control | Q24299106 | ||
| YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response | Q24299975 | ||
| RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor | Q24301371 | ||
| The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to Bax conformational change and cell death | Q24305092 | ||
| Newly identified stress-responsive protein kinases, Krs-1 and Krs-2 | Q24308319 | ||
| Novel type of Ras effector interaction established between tumour suppressor NORE1A and Ras switch II | Q24309371 | ||
| Identification of Nore1 as a potential Ras effector | Q24314874 | ||
| The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20-like kinases MST1 and MST2. | Q24322848 | ||
| Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling | Q24323370 | ||
| The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by disrupting the MDM2-DAXX-HAUSP complex | Q24323508 | ||
| Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a | Q24324559 | ||
| Role of the tumor suppressor RASSF2 in regulation of MST1 kinase activity | Q24336042 | ||
| Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras | Q24338128 | ||
| RASSF2 associates with and stabilizes the proapoptotic kinase MST2 | Q24338394 | ||
| Protein phosphatase 1alpha is a Ras-activated Bad phosphatase that regulates interleukin-2 deprivation-induced apoptosis | Q24594034 | ||
| The Hippo Signaling Pathway in Development and Cancer | Q24603986 | ||
| Wnt/beta-catenin signaling: components, mechanisms, and diseases | Q24630938 | ||
| RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein | Q24648062 | ||
| A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization | Q24669694 | ||
| RASSF tumor suppressor gene family: biological functions and regulation | Q26866080 | ||
| PP1 and PP2A phosphatases--cooperating partners in modulating retinoblastoma protein activation | Q26991427 | ||
| The tumor suppressor gene, RASSF1A, is essential for protection against inflammation -induced injury | Q27305276 | ||
| The retinoblastoma protein and cell cycle control | Q27860722 | ||
| Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis | Q28139203 | ||
| The pro-apoptotic Ras effector Nore1 may serve as a Ras-regulated tumor suppressor in the lung | Q28188823 | ||
| The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas | Q28190533 | ||
| Identification of a novel Ras-regulated proapoptotic pathway | Q28203664 | ||
| Apoptotic phosphorylation of histone H2B is mediated by mammalian sterile twenty kinase | Q28205257 | ||
| Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2 | Q28210189 | ||
| Protein phosphatases 1 and 2A promote Raf-1 activation by regulating 14-3-3 interactions | Q28211695 | ||
| RASSF3 and NORE1: identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1 | Q28215344 | ||
| Specificity of the methylation-suppressed A isoform of candidate tumor suppressor RASSF1 for microtubule hyperstabilization is determined by cell death inducer C19ORF5 | Q28238668 | ||
| PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth | Q28243336 | ||
| RAS oncogenes: weaving a tumorigenic web | Q28250360 | ||
| RASSF1A interacts with microtubule-associated proteins and modulates microtubule dynamics | Q28267593 | ||
| CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer | Q28283044 | ||
| Ablation of Rassf2 induces bone defects and subsequent haematopoietic anomalies in mice | Q28509403 | ||
| RASSF6 is a novel member of the RASSF family of tumor suppressors | Q28509722 | ||
| Menin determines K-RAS proliferative outputs in endocrine cells | Q28589291 | ||
| Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers | Q34570590 | ||
| Silencing of RASSF3 by DNA hypermethylation is associated with tumorigenesis in somatotroph adenomas | Q34650707 | ||
| Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner | Q34676703 | ||
| The RASSF1A tumor suppressor regulates XPA-mediated DNA repair | Q34968548 | ||
| Promoter methylation status of Ras-association domain family members in pheochromocytoma | Q35099523 | ||
| Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma | Q35126668 | ||
| Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis | Q35132940 | ||
| Competing to coordinate cell fate decisions: the MST2-Raf-1 signaling device | Q35158033 | ||
| Deletion of Rb accelerates pancreatic carcinogenesis by oncogenic Kras and impairs senescence in premalignant lesions | Q35186531 | ||
| The dark side of Ras: regulation of apoptosis | Q35603375 | ||
| Clinical utility of RASSF1A methylation in human malignancies | Q35909621 | ||
| Intrinsic tumour suppression | Q35953133 | ||
| RASSF1A and the rs2073498 Cancer Associated SNP | Q35971247 | ||
| Regulation of cell cycle progression and nuclear affinity of the retinoblastoma protein by protein phosphatases. | Q36050995 | ||
| Role of the Ras-association domain family 1 tumor suppressor gene in human cancers | Q36113844 | ||
| Modulator of apoptosis 1 (MOAP-1) is a tumor suppressor protein linked to the RASSF1A protein. | Q36115786 | ||
| Mdm2 associates with Ras effector NORE1 to induce the degradation of oncoprotein HIPK1 | Q28592139 | ||
| The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism | Q29547302 | ||
| Live or let die: the cell's response to p53 | Q29547663 | ||
| ras oncogenes in human cancer: a review | Q29547769 | ||
| Ras oncogenes: split personalities | Q29615405 | ||
| Caught up in a Wnt storm: Wnt signaling in cancer | Q29617494 | ||
| A hitchhiker's guide to the cullin ubiquitin ligases: SCF and its kin | Q29618006 | ||
| NORE1A is a Ras senescence effector that controls the apoptotic/senescent balance of p53 via HIPK2. | Q30370843 | ||
| Ras history: The saga continues | Q30404024 | ||
| A RASSF1A polymorphism restricts p53/p73 activation and associates with poor survival and accelerated age of onset of soft tissue sarcoma | Q30413809 | ||
| A comprehensive survey of Ras mutations in cancer | Q30416821 | ||
| Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. | Q30884723 | ||
| The Ras-association domain family (RASSF) members and their role in human tumourigenesis | Q31121564 | ||
| ATR and ATM differently regulate WRN to prevent DSBs at stalled replication forks and promote replication fork recovery | Q33292088 | ||
| High mutability of the tumor suppressor genes RASSF1 and RBSP3 (CTDSPL) in cancer | Q33455585 | ||
| Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer | Q33591673 | ||
| Epigenetic inactivation of the NORE1gene correlates with malignant progression of colorectal tumors | Q33726187 | ||
| RASSF6 promotes p21(Cip1/Waf1)-dependent cell cycle arrest and apoptosis through activation of the JNK/SAPK pathway in clear cell renal cell carcinoma | Q33728900 | ||
| Cross-regulation between oncogenic BRAF(V600E) kinase and the MST1 pathway in papillary thyroid carcinoma | Q33797782 | ||
| Mst1 promotes cardiac myocyte apoptosis through phosphorylation and inhibition of Bcl-xL | Q33819193 | ||
| The Ras effector RASSF2 controls the PAR-4 tumor suppressor | Q33877015 | ||
| Understanding Ras: 'it ain't over 'til it's over'. | Q33877218 | ||
| The importance of being K-Ras | Q34034093 | ||
| Ras and Rho GTPases: a family reunion | Q34073399 | ||
| Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. | Q34108288 | ||
| Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism | Q34140558 | ||
| Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer. | Q34168295 | ||
| Tumor Suppressor Ras Association Domain Family 5 (RASSF5/NORE1) Mediates Death Receptor Ligand-induced Apoptosis | Q34251431 | ||
| Oncogenic ras and p53 cooperate to induce cellular senescence | Q34279104 | ||
| The MDM2-p53 interaction. | Q34288001 | ||
| Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. | Q34379673 | ||
| The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer | Q34433428 | ||
| Ras regulates SCF(β-TrCP) protein activity and specificity via its effector protein NORE1A. | Q34467504 | ||
| Cell cycle restriction is more important than apoptosis induction for RASSF1A protein tumor suppression | Q34467580 | ||
| The RASSF1A tumor suppressor activates Bax via MOAP-1. | Q34475337 | ||
| Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. | Q34498682 | ||
| The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias | Q39830585 | ||
| RASSF1A mediates p21Cip1/Waf1-dependent cell cycle arrest and senescence through modulation of the Raf-MEK-ERK pathway and inhibition of Akt. | Q39882775 | ||
| RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs. | Q39963026 | ||
| Epigenetic inactivation of RASSF2 in oral squamous cell carcinoma. | Q40009864 | ||
| Ras-association domain family protein 6 induces apoptosis via both caspase-dependent and caspase-independent pathways | Q40157708 | ||
| Ras association domain family 1C protein stimulates human lung cancer cell proliferation | Q40246812 | ||
| Involvement of the RASSF1A tumor suppressor gene in controlling cell migration | Q40377886 | ||
| RASSF4/AD037 is a potential ras effector/tumor suppressor of the RASSF family. | Q40485735 | ||
| Aberrant methylation of RASSF4/AD037 in nasopharyngeal carcinoma. | Q40514524 | ||
| Inactivation of RASSF1C during in vivo tumor growth identifies it as a tumor suppressor gene | Q40543079 | ||
| A role for the RASSF1A tumor suppressor in the regulation of tubulin polymerization and genomic stability | Q40543835 | ||
| NORE1A Regulates MDM2 Via β-TrCP. | Q40681916 | ||
| Protein interaction switches coordinate Raf-1 and MST2/Hippo signalling | Q42152409 | ||
| Loss of RASSF2 Enhances Tumorigencity of Lung Cancer Cells and Confers Resistance to Chemotherapy | Q42184843 | ||
| The Drosophila RASSF homolog antagonizes the hippo pathway | Q42236170 | ||
| Proapoptotic Rassf1A/Mst1 signaling in cardiac fibroblasts is protective against pressure overload in mice | Q42416763 | ||
| NORE1A tumor suppressor candidate modulates p21CIP1 via p53. | Q42799756 | ||
| Tumour biology: senescence in premalignant tumours | Q42802962 | ||
| A negative feedback signaling network underlies oncogene-induced senescence | Q43116108 | ||
| Protein phosphatase 1alpha-mediated stimulation of apoptosis is associated with dephosphorylation of the retinoblastoma protein | Q43761465 | ||
| Control of microtubule stability by the RASSF1A tumor suppressor | Q44645799 | ||
| Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma | Q47445963 | ||
| ATR kinase as master regulator of nucleotide excision repair during S phase of the cell cycle | Q47806230 | ||
| Nore1 inhibits tumor cell growth independent of Ras or the MST1/2 kinases | Q47984176 | ||
| RASSF3 downregulation increases malignant phenotypes of non-small cell lung cancer. | Q50752468 | ||
| PPP1CA contributes to the senescence program induced by oncogenic Ras. | Q53325013 | ||
| Genetic and epigenetic profiling in early colorectal tumors and prediction of invasive potential in pT1 (early invasive) colorectal cancers. | Q53338659 | ||
| Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. | Q53347351 | ||
| Ras-driven proliferation and apoptosis signaling during rat liver carcinogenesis is under genetic control. | Q53460647 | ||
| Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer | Q53649603 | ||
| Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras. | Q54541000 | ||
| Nuclear transport of Ras-associated tumor suppressor proteins: different transport receptor binding specificities for arginine-rich nuclear targeting signals. | Q55043344 | ||
| RASSF1C, an Isoform of the Tumor Suppressor RASSF1A, Promotes the Accumulation of β-Catenin by Interacting with βTrCP | Q61824843 | ||
| NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers | Q72992695 | ||
| MST1-JNK promotes apoptosis via caspase-dependent and independent pathways | Q74152681 | ||
| High frequency somatic mutations in RASSF1A in nasopharyngeal carcinoma | Q81050017 | ||
| Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient's follow-up | Q81405822 | ||
| Recognizing and defining true Ras binding domains I: biochemical analysis | Q81643533 | ||
| PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients | Q84609988 | ||
| Decreased expression and aberrant methylation of RASSF5A correlates with malignant progression of gastric cardia adenocarcinoma | Q86046632 | ||
| RASSF1A Suppresses the Invasion and Metastatic Potential of Human Non-Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB Pathway | Q87063270 | ||
| RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells | Q36216004 | ||
| The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma | Q36383883 | ||
| Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer | Q36394050 | ||
| Ras Regulates Rb via NORE1A. | Q36548478 | ||
| Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation | Q36556010 | ||
| Critical Tyrosine Residues Regulate the Enzymatic and Biological Activity of Raf-1 Kinase | Q36826443 | ||
| Senescence in tumours: evidence from mice and humans | Q36903843 | ||
| The RASSF1A tumor suppressor | Q36945316 | ||
| DNA damage signalling guards against activated oncogenes and tumour progression | Q37027188 | ||
| Rassf family of tumor suppressor polypeptides. | Q37353443 | ||
| Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression | Q37410567 | ||
| The N-terminal RASSF family: a new group of Ras-association-domain-containing proteins, with emerging links to cancer formation | Q37660499 | ||
| Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells. | Q37761824 | ||
| Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis | Q37903701 | ||
| DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis | Q37977244 | ||
| Controversial aspects of oncogene-induced senescence | Q38055308 | ||
| The Hippo pathway: regulators and regulations | Q38083640 | ||
| Inside and out: the activities of senescence in cancer. | Q38230319 | ||
| Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice. | Q38357380 | ||
| Forging a signature of in vivo senescence | Q38536371 | ||
| NORE1A induction by membrane-bound CD40L (mCD40L) contributes to CD40L-induced cell death and G1 growth arrest in p21-mediated mechanism | Q38785550 | ||
| RASSF1A Directly Antagonizes RhoA Activity through the Assembly of a Smurf1-Mediated Destruction Complex to Suppress Tumorigenesis | Q38798230 | ||
| Alternate RASSF1 Transcripts Control SRC Activity, E-Cadherin Contacts, and YAP-Mediated Invasion | Q38821010 | ||
| RASSF4 is downregulated in nonsmall cell lung cancer and inhibits cancer cell proliferation and invasion | Q38822769 | ||
| RASSF5A, a candidate tumor suppressor, is epigenetically inactivated in esophageal squamous cell carcinoma | Q38920937 | ||
| RASSF1A-LATS1 signalling stabilizes replication forks by restricting CDK2-mediated phosphorylation of BRCA2. | Q38956821 | ||
| RASSF1A inactivation unleashes a tumor suppressor/oncogene cascade with context-dependent consequences on cell cycle progression | Q39004151 | ||
| The RASSF6 tumor suppressor protein regulates apoptosis and the cell cycle via MDM2 protein and p53 protein. | Q39100434 | ||
| Small proline-rich protein-1B is overexpressed in human oral squamous cell cancer stem-like cells and is related to their growth through activation of MAP kinase signal | Q39108870 | ||
| Epstein-Barr virus latent membrane protein 1 increases genomic instability through Egr-1-mediated up-regulation of activation-induced cytidine deaminase in B-cell lymphoma | Q39202093 | ||
| The RASSF3 candidate tumor suppressor induces apoptosis and G1-S cell-cycle arrest via p53. | Q39347028 | ||
| Proteomics Analysis Reveals Novel RASSF2 Interaction Partners | Q39583823 | ||
| Functional importance of RASSF1A microtubule localization and polymorphisms | Q39669245 | ||
| ATM regulates a RASSF1A-dependent DNA damage response | Q39766802 | ||
| Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma | Q39779862 | ||
| Hippo pathway-dependent and -independent roles of RASSF6. | Q39792600 | ||
| P304 | page(s) | 86-95 | |
| P577 | publication date | 2016-06-08 | |
| P1433 | published in | Seminars in Cell & Developmental Biology | Q14330411 |
| P1476 | title | Ras signaling through RASSF proteins | |
| P478 | volume | 58 |
| Q42358747 | A Fungus-Specific Protein Domain Is Essential for RasA-Mediated Morphogenetic Signaling in Aspergillus fumigatus |
| Q91889015 | Autoinhibition in Ras effectors Raf, PI3Kα, and RASSF5: a comprehensive review underscoring the challenges in pharmacological intervention |
| Q91310911 | Cancer and RASSF1A/RASSF1C, the Two Faces of Janus |
| Q55433301 | Changes in mRNA/protein expression and signaling pathways in in vivo passaged mouse ovarian cancer cells. |
| Q91675504 | Does Ras Activate Raf and PI3K Allosterically? |
| Q60923649 | IRF1 inhibits the proliferation and metastasis of colorectal cancer by suppressing the RAS-RAC1 pathway |
| Q38891078 | Intracellular and intercellular signaling networks in cancer initiation, development and precision anti-cancer therapy: RAS acts as contextual signaling hub. |
| Q39361391 | Intrinsic protein disorder in oncogenic KRAS signaling |
| Q38736586 | Long noncoding RNA CRNDE stabilized by hnRNPUL2 accelerates cell proliferation and migration in colorectal carcinoma via activating Ras/MAPK signaling pathways |
| Q33821181 | MST1/MST2 Protein Kinases: Regulation and Physiologic Roles |
| Q92757939 | MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells |
| Q64082641 | New type of interaction between the SARAH domain of the tumour suppressor RASSF1A and its mitotic kinase Aurora A |
| Q40370739 | Nonstructural protein 5B promotes degradation of the NORE1A tumor suppressor to facilitate hepatitis C virus replication |
| Q47256433 | Oncogenic Ras Isoforms Signaling Specificity at the Membrane |
| Q51256539 | Overexpression of RAS-Association Domain Family 6 (RASSF6) Inhibits Proliferation and Tumorigenesis in Hepatocellular Carcinoma Cells. |
| Q38765858 | PDEδ Binding to Ras Isoforms Provides a Route to Proper Membrane Localization. |
| Q60955118 | Perspectives of RAS and RHEB GTPase Signaling Pathways in Regenerating Brain Neurons |
| Q89636636 | Pumping the brakes on RAS - negative regulators and death effectors of RAS |
| Q88595370 | RASSF1A Deficiency Enhances RAS-Driven Lung Tumorigenesis |
| Q92811214 | RASSF1A Tumour Suppressor: Target the Network for Effective Cancer Therapy |
| Q91717152 | RASSF1A, puppeteer of cellular homeostasis, fights tumorigenesis, and metastasis-an updated review |
| Q64078199 | Regulation Mechanism of Long Noncoding RNAs in Colon Cancer Development and Progression |
| Q64912822 | The Cross-Talk Between the TNF-α and RASSF-Hippo Signalling Pathways. |
| Q36217950 | The RAS-Effector Interface: Isoform-Specific Differences in the Effector Binding Regions |
| Q92878196 | The different expression of tumor suppressors, RASSF1A, RUNX3, and GSTP1, in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH) |
| Q47566645 | The dynamic mechanism of RASSF5 and MST kinase activation by Ras. |
| Q64973410 | The role of RASSF proteins in modulating RAS driven lung tumors in vivo. |
| Q39271171 | The role of the NORE1A tumor suppressor in Oncogene-Induced Senescence |
| Q57929374 | UNC119 is a binding partner of tumor suppressor Ras-association domain family 6 and induces apoptosis and cell cycle arrest by MDM2 and p53 |
| Q64081398 | experimental models account for higher complexity than preclinical settings in cancer |
Search more.